| Host: | Mouse |
| Applications: | WB/IHC-P/ICC/IF/ELISA |
| Reactivity: | Vertebrates |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description : | Mouse monoclonal anti-IDH2-R140Q Mutant for use in WB, IHC-P, ICC, IF and ELISA in Vertebrates samples. Datasheet included with dilution recommendations, and related reagents. |
| Clonality : | Monoclonal |
| Conjugation: | Unconjugated |
| Isotype: | IgG |
| Formulation: | Liquid in PBS (without Mg2+ and Ca2+) , pH 7.4, 150 mM NaCl, 50% glycerol |
| Purification: | Purified from ascites |
| Dilution Range: | ELISA-1:1000-1:5000WB-1:500-1:1000ICC/IF-1:50-1:100IHC-P-1:50-1:100 |
| Storage Instruction: | Store at-20°C. Avoid freeze/thaw cycles. |
| Immunogen: | A synthetic peptide from the internal region of IDH2 which includes the mutation of R140Q, human origin. |
| Background | Isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of isocitrate to 2-oxoglutarate. Mutations of Arg-132 in IDH to Cys, His, Leu or Ser abolish magnesium binding and the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R-2-hydroxyglutarate. Elevated levels of R-2-hydroxyglutarate are correlated with an elevated risk of malignant brain tumors. |
Information sourced from Uniprot.org